# A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

> **NCT00094367** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 900 (—)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Abacavir/Lamivudine

## Key facts

- **NCT ID:** NCT00094367
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 900 (—)
- **Last updated:** 2010-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094367, "A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00094367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*